PDT Partners LLC Boosts Stake in Cellebrite DI Ltd. $CLBT

Key Points

• PDT Partners LLC increased its stake in Cellebrite DI Ltd. by 67.5%, owning 205,732 shares valued at nearly $4 million as of the latest SEC filing.
• Wall Street analysts have mixed ratings on Cellebrite DI, with a consensus rating of "Buy" and a target price of $22.40, while individual ratings vary with some analysts lowering their price targets.
• Cellebrite DI reported a quarterly revenue of $113.28 million, surpassing analysts' expectations, with a year-over-year increase of 18.4%.

PDT Partners LLC grew its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 67.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 205,732 shares of the company's stock after acquiring an additional 82,890 shares during the period. PDT Partners LLC owned about 0.09% of Cellebrite DI worth $3,997,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Bosun Asset Management LLC raised its position in shares of Cellebrite DI by 1.4% in the fourth quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock worth $954,000 after acquiring an additional 584 shares during the period. OneDigital Investment Advisors LLC raised its position in shares of Cellebrite DI by 2.5% in the first quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after acquiring an additional 688 shares during the period. Assetmark Inc. acquired a new position in shares of Cellebrite DI in the first quarter worth about $33,000. HighTower Advisors LLC raised its position in shares of Cellebrite DI by 16.3% in the first quarter. HighTower Advisors LLC now owns 14,485 shares of the company's stock worth $281,000 after acquiring an additional 2,029 shares during the period. Finally, Catalyst Capital Advisors LLC acquired a new position in shares of Cellebrite DI in the first quarter worth about $51,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CLBT shares. JPMorgan Chase & Co. decreased their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. Finally, Lake Street Capital cut their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $22.40.

Cellebrite DI Price Performance

NASDAQ CLBT traded up $0.24 during trading hours on Friday, hitting $16.61. 1,514,434 shares of the company's stock traded hands, compared to its average volume of 1,695,406. Cellebrite DI Ltd. has a 52-week low of $13.10 and a 52-week high of $26.30. The company has a market capitalization of $3.98 billion, a PE ratio of -21.86, a PEG ratio of 3.00 and a beta of 1.28. The firm's 50-day moving average is $15.01 and its 200-day moving average is $17.06.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's revenue was up 18.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.